September 19, 2017 – Raleigh, NC

MAA Laboratories has been awarded an NIH Phase I Small Business Innovation Research (SBIR) grant. Awarded via the National Cancer Institute, an institute of the NIH, the SBIR grant will provide non-dilutive funding to MAA Laboratories to develop a novel formulation of an anti-leukemia drug product, which currently has significant deficiencies related to dosing and bioavailability.The goal of the project is to use MAA’s proprietary NanoCont^TM technology to create an anti-leukemia drug product with markedly improve performance, which will provide an improved therapeutic option for patients with leukemia. 

August 30, 2017 – Raleigh, NC

MAA Laboratories has received a grant from the One N.C. Small Business Program. The award is based on the successful funding of MAA Laboratories’ Phase I SBIR grant from the National Science Foundation. The NSF SBIR grant was funded to further develop the company’s NanoCont^TM drug development technology. One N.C. matching funds will be used to accelerate the development of MAA Laboratories pipeline products through pre-clinical testing. 

June 1, 2017 – Raleigh, NC

MAA Laboratories has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation. The SBIR grant will provide non-dilutive funding to MAA Laboratories to further develop the company’s NanoCont^TM drug development technology. 

February 21, 2017 – Raleigh, NC

Dr. Anjani Jha, founder and CEO of MAA Laboratories, will join several other biotechnology executives to discuss the current status and the future of life science innovations. The discussion panel, titled “Life Science Companies Changing the World,” will be held on Thursday, February 28 as part of the Council for Entrepreneurial Development (CED) Life Science Conference at the Raleigh Convention Center.

November 25, 2016 – Raleigh, NC

MAA Laboratories has appointed Mr. Pieter de Ridder as Chief Business Officer.  Mr. Pieter Ridder has over 20 years of global leadership experience in business development and commercial operations of generics and biotechnology companies.